Monday, October 26, 2026 · Daily editionET --:--:--

Finished

ACE2 Gender Differences in Stroke With COVID-19

NCT04766645 · Fondazione Don Carlo Gnocchi ETS · Updated 18 July 2023

What is being tested
Robotic assisted intervention; epigenetic analyses; biochemical analyses
For
Neurologic Manifestations
Kind of study
Watches patients without assigning a treatment. No drug phase (a device or procedure study).
Who can join
Ages 18 years to 90 years. About 77 people. The full rules are on the registry page.
Where
Italy
When
Starts or started 4 Sept 2020, ends 31 Jan 2023. Registered 23 Feb 2021.
Results
None posted yet.

In the researchers' words

The new coronavirus SARS-CoV-2, causes the COVID-19 infection, which showed a form of neurovirulence involving the Central and peripheral Nervous Systems \[Baig et al, 2020\]. In a mouse model for human ACE2 expression, the virus entered the brain mainly through the olfactory bulb pathway \[Netland et al, 2008\], with an encephalic invasion uniformly lethal even with low viral doses and without lung involvement. The death of the animal was reasonably related to neuronal dysfunction/death in cardiorespiratory bone marrow centers, while the absence of ACE2 prevented severe encephalopathy. Men has a highly frequency of severe and lethal COVID-19, and the observed gender difference could be related to the regulation of ACE2 receptor expression. The ACE2 gene is encoded by a region of the X chromosome that escapes inactivation, so that women have an increased expression of this protein. The process of inactivation of the X chromosome includes DNA methylation with a decrease in the expression of genes that are affected by methylation. In This way an epigenetic mechanism could modulate the expression of ACE2 in a gender-specific way determining its levels and consequently its protective role. Also in this regulatory context of ACE2 expression the role of microRNA (miRNA) could be very important. In fact, the untranslated 3' region (UTR) of ACE2 presents a binding sequence for…
ClinicalTrials.gov, NCT04766645

Sites

  • Fondazione Don Carlo GnocchiRome, Italy